June 3-7 | Chicago, IL | Booth #24085
Join us at the 2022 ASCO Annual Meeting
Our experts are leveraging breakthrough science, clinical data and patient insights to power better decisions and improve patient outcomes across the cancer spectrum.
Labcorp Oncology accepted posters and publications
| Title | First Author | Format | Track | Date | Time |
|---|---|---|---|---|---|
| Mutational landscape and clinical characterization of over 17,000 patients with myeloid malignancies using real world data | Grant Hogg | Poster | Hematologic Malignancies | Saturday June 4, 2022 | 8:00 AM - 11:00 AM CDT |
| Comprehensive genomic and immune profiling defines immunotherapy treatment in NSCLC patients with low PD-L1 IHC | Sarabjot Pabla | Poster | Developmental Therapeutics—Immunotherapy | Sunday June 5, 2022 | 8:00 AM - 11:00 AM CDT |
| Comprehensive genomic profiling: insights into diagnostic value and treatment strategy | Michelle Shiller | Publication | Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology | Sunday June 5, 2022 | 8:00 AM - 11:00 AM CDT |
| Comprehensive transcriptomic analysis of immune checkpoint markers in a pan-cancer cohort: Implications for response and resistance | Hirotaka Miyashita | Poster | Developmental Therapeutics—Immunotherapy | Sunday June 5, 2022 | 8:00 AM - 11:00 AM CDT |
| First-in-human (FIH) phase I study of the highly selective phosphoinositide 3-kinase inhibitor delta (PI3Kδ) inhibitor IOA-244 in patients with advanced cancer: Safety, activity, pharmacokinetic (PK), pharmacodynamic (PD) results | Anna Di Giacomo | Poster | Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology | Sunday June 5, 2022 | 8:00 AM - 11:00 AM CDT |
| Justifying integration of liquid biopsy into routine molecular diagnostics to complement tissue genomic profiling: Experience at Fox Chase Cancer Center | Don A. Bladwin | Publication | Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology | Sunday June 5, 2022 | 8:00 AM - 11:00 AM CDT |
| LAG3 transcriptomic expression correlates with high levels of PD-1, PD-L1, PD-L2, and CTLA-4 checkpoints and with high tumor mutational burden across cancers | Jacob Adashek | Poster | Developmental Therapeutics—Immunotherapy | Sunday June 5, 2022 | 8:00 AM - 11:00 AM CDT |
| A Multicenter, Open Label, Phase 1a/b Study of HC-7366, a Modulator of Integrated Stress Response (ISR) Kinase GCN2 in Subjects with Advanced Solid Tumors | Meredith Pelster | Poster | Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology | Sunday June 5, 2022 | 8:00 AM - 11:00 AM CDT |
| Comprehensive genomic and immune profiling (CGIP) treatment patterns and survival in non-small cell lung cancer (NSCLC) | Mary K. Nesline | Publication | Monday June 6, 2022 | 8:00 AM - 11:00 AM CDT |